2-cyano-chromane | 89197-58-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 2-cyano-chromane
• 英文别名: 2-cyanochroman；2-cyanochromane；Chroman-2-carbonitrile；3,4-dihydro-2H-chromene-2-carbonitrile
• CAS: 89197-58-0
• 化学式: C₁₀H₉NO
• 分子量: 159.188
• InChiKey: PSODBWOLLYALSQ-UHFFFAOYSA-N

物化性质

• 沸点：
  321.1±31.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-cyano-chromane 在 盐酸 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 48.0h， 生成 2-chromanyl-2-imidazoline
  参考文献：
  名称：

  .alpha.-Adrenoceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on .alpha.-adrenoreceptor activity

  摘要：

  Modification of the 1,4-benzodioxan ring present in RX 781094 has not previously been considered. This paper describes a number of analogues of this ring system, including compounds in which one of the oxygen atoms has been replaced by a methylene group and also those in which the ring size has been changed to give, for example, furan and thiophene derivatives. The dihydrobenzofuranylimidazoline compound 7 is the only analogue possessing presynaptic antagonist potency potency and selectivity comparable to that of 1. In view of this result, a number of derivatives was prepared to determine the structure-activity relationships within this series. Many derivatives, as well as the parent compound 7, were found to possess presynaptic alpha 2-adrenoreceptor antagonist and postsynaptic alpha 1-adrenoreceptor partial agonist properties. Two of the selective presynaptic antagonists, 13 and 14 possess greater potency and selectivity than that possessed by 1. The 5-chloro derivative 25 is twice as potent as after oral administration but only about half as potent when given intravenously.

  DOI：

  10.1021/jm00371a003
• 作为产物：
  描述：

  苯并二氢吡喃-2-羧酸 在 氯化亚砜 、 氨 、 phosphorus pentoxide 作用下， 以 1,4-二氧六环 、 甲苯 、 苯 为溶剂， 反应 22.5h， 生成 2-cyano-chromane
  参考文献：
  名称：

  .alpha.-Adrenoceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on .alpha.-adrenoreceptor activity

  摘要：

  Modification of the 1,4-benzodioxan ring present in RX 781094 has not previously been considered. This paper describes a number of analogues of this ring system, including compounds in which one of the oxygen atoms has been replaced by a methylene group and also those in which the ring size has been changed to give, for example, furan and thiophene derivatives. The dihydrobenzofuranylimidazoline compound 7 is the only analogue possessing presynaptic antagonist potency potency and selectivity comparable to that of 1. In view of this result, a number of derivatives was prepared to determine the structure-activity relationships within this series. Many derivatives, as well as the parent compound 7, were found to possess presynaptic alpha 2-adrenoreceptor antagonist and postsynaptic alpha 1-adrenoreceptor partial agonist properties. Two of the selective presynaptic antagonists, 13 and 14 possess greater potency and selectivity than that possessed by 1. The 5-chloro derivative 25 is twice as potent as after oral administration but only about half as potent when given intravenously.

  DOI：

  10.1021/jm00371a003

文献信息

• [EN] BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF<br/>[FR] COMPOSES BICYCLIQUES PRESENTANT UNE AFFINITE POUR LES RECEPTEURS DE LA BRADYKININE ET COMPOSITIONS PHARMACEUTIQUES EN CONTENANT
  申请人：AMGEN INC

  公开号：WO2004092116A1

  公开（公告）日：2004-10-28

  Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于治疗疼痛和炎症介导的疾病等方面有效。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的衍生物，以及用于预防和治疗涉及疼痛、炎症等疾病和其他疾病或病况的药物组合物和方法。该发明还涉及制备这类化合物的方法，以及在这类方法中有用的中间体。
• [EN] CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ<br/>[FR] DERIVES AMINES CYCLIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES LIES A L'INFLAMMATION INDUITS PAR LA BRADYKININE
  申请人：AMGEN INC

  公开号：WO2004092164A1

  公开（公告）日：2004-10-28

  Compounds of formula (I) are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation mediated by Bradykinin. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes wherein q, t, R, Ra, Rb, Rc and R2 are as defined herein.

  公式（I）的化合物对于治疗疼痛和疾病，如由炎症介导的疾病，具有有效性。该发明涵盖了新型化合物，其药学上可接受的衍生物，药物组合物以及用于预防和治疗涉及疼痛、由Bradykinin介导的炎症等疾病和其他疾病或病况的方法。该发明还涉及制备此类化合物的方法，以及在这些方法中有用的中间体，其中q、t、R、Ra、Rb、Rc和R2如本文所定义。
• Cyclic amine derivatives and methods of use
  申请人：Groneberg D. Robert

  公开号：US20050234044A1

  公开（公告）日：2005-10-20

  Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的化合物对于治疗疼痛和疾病，如炎症介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的衍生物，药物组合物以及用于预防和治疗涉及疼痛、炎症等疾病和其他疾病或病症的方法。该发明还涉及制备这些化合物的过程，以及在这些过程中有用的中间体。
• Pyridyl chroman
  申请人：Merck Patent Gesellschaft Mit Beschrankter Haftung

  公开号：US05767132A1

  公开（公告）日：1998-06-16

  Amino(thio)ether derivatives of formula I ##STR1## wherein R.sup.0, R.sup.1, R.sup.2, R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.9, X and Z are as defined herein, and their salts, are active on the central nervous system.

  公式I的氨基（硫）醚衍生物##STR1## 其中，R.sup.0、R.sup.1、R.sup.2、R.sup.3、R.sup.6、R.sup.7、R.sup.8、R.sup.9、X和Z的定义如本文所述，并且它们的盐对中枢神经系统有活性。
• Compounds and methods of use
  申请人：Groneberg D. Robert

  公开号：US20050124654A1

  公开（公告）日：2005-06-09

  Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于治疗疼痛和炎症介导的疾病等方面有效。该发明包括新颖的化合物、类似物、前药和其药学上可接受的衍生物、制药组合物以及预防和治疗涉及疼痛、炎症等疾病和其他疾病或病况的方法。该发明还涉及制备这种化合物的过程以及在这种过程中有用的中间体。